Literature DB >> 7697443

Clinical spectrum of HTLV-I in south Florida.

W J Harrington1, A Ucar, P Gill, S Snodgrass, W Sheremata, L Cabral, M Rabin, G E Byrne, J Berger, W Voight.   

Abstract

A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4% lifetime risk of developing ATLL and an additional 0.25% lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7697443     DOI: 10.1097/00042560-199504120-00006

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  8 in total

Review 1.  Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.

Authors:  Kenneth E Ugen; Susan B Nyland
Journal:  Springer Semin Immunopathol       Date:  2006-10-13

Review 2.  Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran.

Authors:  Mohammad Reza Hedayati-Moghaddam; Reza Jafarzadeh Esfehani; Hiba El Hajj; Ali Bazarbachi
Journal:  Viruses       Date:  2022-03-23       Impact factor: 5.818

3.  Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States.

Authors:  Luis Malpica; Agustin Pimentel; Isildinha M Reis; Eduardo Gotuzzo; Lazaros Lekakis; Krishna Komanduri; Thomas Harrington; Glen N Barber; Juan C Ramos
Journal:  Blood Adv       Date:  2018-03-27

4.  Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: is it safe?

Authors:  Michael R Marvin; Guy N Brock; Kwadwo Kwarteng; Ravi Nagubandi; Kadiyala V Ravindra; Mary Eng; Joseph F Buell
Journal:  Transplantation       Date:  2009-04-27       Impact factor: 4.939

5.  Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity.

Authors:  W Matsuyama; M Kawabata; A Mizoguchi; F Iwami; J Wakimoto; M Osame
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

6.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

7.  Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Misako Nagasaka; Makoto Yamagishi; Naoko Yagishita; Natsumi Araya; Seiichiro Kobayashi; Junya Makiyama; Miyuki Kubokawa; Junji Yamauchi; Daisuke Hasegawa; Ariella L G Coler-Reilly; Shuntaro Tsutsumi; Yu Uemura; Ayako Arai; Ayako Takata; Eisuke Inoue; Yasuhiro Hasegawa; Toshiki Watanabe; Yutaka Suzuki; Kaoru Uchimaru; Tomoo Sato; Yoshihisa Yamano
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-11       Impact factor: 11.205

8.  Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P).

Authors:  Junji Yamauchi; Kenichiro Tanabe; Tomoo Sato; Masanori Nakagawa; Eiji Matsuura; Yoshio Tsuboi; Keiko Tamaki; Hirokuni Sakima; Satoshi Ishihara; Yuki Ohta; Naoki Matsumoto; Kenichi Kono; Naoko Yagishita; Natsumi Araya; Katsunori Takahashi; Yasuo Kunitomo; Misako Nagasaka; Ariella Coler-Reilly; Yasuhiro Hasegawa; Abelardo Araujo; Steven Jacobson; Maria Fernanda Rios Grassi; Bernardo Galvão-Castro; Martin Bland; Graham P Taylor; Fabiola Martin; Yoshihisa Yamano
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.